<DOC>
	<DOCNO>NCT02130193</DOCNO>
	<brief_summary>The aim First Time Patient study obtain initial information safety , tolerability , pharmacokinetics , pharmacodynamics clinical efficacy repeat daily administration danirixin subject symptomatic chronic obstructive pulmonary disease ( COPD ) mild moderate airflow limitation high risk future COPD exacerbation . The study conduct two part . Part A two week open label , single arm study patient COPD obtain pharmacokinetic data safety information repeat dose danirixin population interest . Approximately 10 subject enrol Part A study . Progression dose selection Part B occur follow review data collect Part A . Part B 52-week , randomize , double-blind ( sponsor unblind ) , placebo-controlled top standard care , parallel group study . Part B evaluate several clinical efficacy assessment related exacerbation respiratory symptom . Approximately 100 subject enrol target 80 subject complete 52 week danirixin administration .</brief_summary>
	<brief_title>Investigation Safety , Tolerability , Pharmacokinetics , Pharmacodynamics , Clinical Efficacy Oral Danirixin Symptomatic COPD Subjects With Mild Moderate Airflow Limitation Risk Exacerbations</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female age 40 70 year age inclusive , time signing informed consent Subjects document history COPD exacerbation ( ) 12 month prior study participation meeting least one follow criterion : &gt; =2 COPD exacerbation result prescription antibiotic and/or oral corticosteroid hospitalization extend observation hospital emergency room outpatient center ; 1 COPD exacerbation result prescription antibiotic and/or oral corticosteroid hospitalization extend observation hospital emergency room outpatient center plasma fibrinogen concentration screen &gt; =3.5 milligram/milliliter ( mg/mL ) Diagnosis symptomatic chronic obstructive pulmonary disease mild moderate airflow obstruction ( COPDGOLD I II ) least 2 year base American Thoracic Society ( ATS ) / European Respiratory Society ( ERS ) current guideline symptom consistent COPD least 2 year Subjects postbronchodilator FEV1/FVC ratio &lt; 0.7 FEV1 &gt; =50 % predict normal value calculate use National Health Nutrition Examination Survey ( NHANES ) III reference equation Visit 1 A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international units/mL ( MIU/mL ) estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 147 picomole/Liter [ pmol/L ] ) confirmatory ] . Females hormone replacement therapy ( HRT ) enrol study . Body weight &gt; =45 kilogram ( kg ) Current smoker former smoker cigarette smoke history &gt; =10 pack year ( 1 pack year =20 cigarette smoke per day 1 year equivalent ) . Former smoker define stop smoke least 6 month prior Visit 1 Subjects history respiratory symptom , include chronic cough and/or mucus hypersecretion day least previous 3 month prior Visit 1 Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Able perform lung function test reliably Based single average correct QT ( QTc ) value triplicate ECGs obtain brief recording period : Fridericiacorrected QTc ( QTcF ) &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block Subjects must ability use electronic diary daily basis [ Part B ] Capable give write informed consent , include compliance requirement restriction list consent form Diagnosis asthma , clinically relevant lung disease ( COPD ) , e.g . sarcoidosis , tuberculosis , pulmonary fibrosis , severe bronchiectasis lung cancer ; Subject alpha1antitrypsin deficiency underlie cause COPD Pulse Oximetry level &lt; 88 % ( rest room air ) screen Less 14 day elapse completion course antibiotic oral corticosteroid recent COPD exacerbation . Diagnosis Pneumonia ( chest XRay compute tomography [ CT ] confirm ) within last 3 month prior screen History current evidence clinically significant renal disease , diabetes mellitus/metabolic syndrome , hypertension clinically significant cardiovascular , neurological , endocrine , hematological abnormality uncontrolled permitted therapy . Significant define disease , opinion Investigator , would put safety subject risk study participation , would affect safety analysis analysis disease/condition exacerbate study . A positive prestudy drug/alcohol screen A positive test human immunodeficiency virus ( HIV ) antibody A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : For non United States America ( US ) sit : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit ; For US site : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Current expect use proton pump inhibitor histamine H2receptor antagonist study period Chest Xray ( posteroanterior lateral ) CT scan reveals evidence pneumonia clinically significant abnormality believe due presence COPD ( historic data 1 yr may use ) . Subjects peripheral blood neutrophil count ( PBN ) &lt; 2x10^9/Liter Subject history previous lung surgery ( e.g . lobectomy , pneumonectomy , lung volume reduction ) Requiring use oral injectable Cytochrome P450 3A4 ( CYP3A4 ) breast cancer resistance protein ( BCRP ) substrates narrow therapeutic index</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Danirixin</keyword>
	<keyword>EXACT-PRO</keyword>
	<keyword>COPD</keyword>
	<keyword>Safety</keyword>
	<keyword>RD</keyword>
	<keyword>CXCR2 inhibitor</keyword>
	<keyword>EXACT-RS</keyword>
	<keyword>PK</keyword>
	<keyword>HCRU exacerbation</keyword>
	<keyword>PD</keyword>
</DOC>